Amedisys, Inc.

AMED
Delayed Nasdaq - 03/27 09:00:00 pm
166.01USD
-0.35%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 2019 2020 (e)
Sales 1 956 2 136
EBITDA 225 256
Operating profit (EBIT) 207 231
Pre-Tax Profit (EBT) 170 225
Net income 127 167
P/E ratio 43,5x 33,2x
EPS ( $ ) 3,84 5,00
Dividend per Share ( $ ) - -
Yield - -
Reference price ( $ ) 166,920 166,010
Announcement Date 02/18/2020
09:15pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 2019 2020 (e)
Debt - 96,9
Finance 0,00 -
Operating income (EBITDA) 225 256
Leverage
(Debt/EBITDA)
- 0,38x
Capital Expenditure - 8,42
Free Cash Flow (FCF) - 153
Book Value Per Share (BVPS) ( $ ) - 25,5
Cash Flow per Share ( $ ) - 4,87
Announcement Date -
Balance Sheet Analysis
Financial Ratios
Size 2020e 2021e
Capitalization 5 364 M $ -
Entreprise Value (EV) 5 461 M $ 5 280 M $
Valuation 2020e 2021e
P/E ratio (Price / EPS) 33,2x 27,7x
Capitalization / Revenue 2,51x 2,34x
EV / Revenue 2,56x 2,38x
EV / EBITDA 21,3x 18,2x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 6,51x 5,24x
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) 10,8% 12,0%
Operating Leverage (Delta EBIT / Delta Sales) 1,27x 2,55x
Net Margin (Net Profit / Revenue) 7,81% 8,86%
ROA (Net Profit / Asset) 12,9% 13,5%
ROE (Net Profit / Equities) 23,3% 22,1%
Rate of Dividend - -
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   0,39% 0,40%
Cash Flow / Sales 7,36% 10,5%
Capital Intensity (Assets / Sales) 0,60x 0,65x
Financial Leverage (Net Debt / EBITDA) 0,38x -
Price Earning Ratio
BNA & Dividende